DECODE Obesity: Pre-Competitive Collaboration To Enhance Obesity Research

GLP-1 therapies have reshaped the obesity drug development landscape, pushing innovation beyond weight loss alone. As treatments grow more powerful and their therapeutic reach widens, the need to capture broader measures of benefit—such as physical function and activity—has never been greater. To address this, Ametris (formerly ActiGraph) has launched DECODE in Obesity, a cross-industry initiative uniting leaders including Eli Lilly, F. Hoffmann-La Roche, and Novo Nordisk.

This collaboration aims to advance evidence generation and regulatory dialogue by integrating mature digital health assessments into obesity trials. In this session of Digital Health Monthly, participants will explore DECODE’s workstreams and objectives, share perspectives on why they joined the initiative, and weigh the opportunities and challenges of deploying digital health technologies (DHTs). From validation strategies to maximizing trial impact, the discussion highlights how DECODE seeks to redefine success in obesity drug development and support stronger clinical and payer outcomes.